Its mechanisms involve stimulating blood vessel formation, promoting cell migration to injury sites, modulating inflammation, and interacting with nitric oxide pathways crucial for sphincter function
You simply come in, receive your injections, and go about your daily life
We believe IA-1 would be achieved by the vast majority of ASM participants with limited effort, which may lessen the concern of initial improvement activity burden and impact to the ASM participant's overall score
Phase 1 (Weeks 1 to 2): 0.25 mg subcutaneous injection once daily, morning on empty stomach Phase 2 (Weeks 3 to 6): Maintain 0.25 mg or increase to 0.5 mg based on response and tolerance Phase 3 (Weeks 7 to 8): Continue or begin taper depending on symptom improvement Maintenance: Consider cycling 4 weeks on, 2 weeks off for long-term management Oral dosing requires higher amounts to compensate for bioavailability differences
In people with severe signs and symptoms, the use of injectable forms of vitamin B12 for several weeks is acknowledged, at least in the initial treatment phase